Quick one.

You can grab my Smart Trade Options Checklist free today — normally $29.97.

It's a one-page filter. Seven checks. Run it before you place any options trade and you'll catch the bad ones before they cost you.

Print it. Keep it next to your screen. Use it on every trade.

Download your free copy right here.

Heads up: That link expires soon.

Grab it now and it's yours.

Good Trading,
Bill Poulos

P.S. The download link expires soon. Once it's gone, the checklist goes back to $29.97. Grab it here.

Accelerant’s Take-Private Deal Raises a Bigger Question for Insurance Stocks

Submitted by Nathan Reiff. Published: 9/4/2026.

Accelerant Holdings (NYSE: ARX) came into focus for investors in mid-August after its shares surged 43% in a single day. This type of share price leap is often reserved for clinical-stage biotech firms announcing breakthrough results, for instance, rather than an unglamorous firm that connects specialty insurance risks across a network of capital providers. Investors, therefore, may underestimate Accelerant's performance potential.

Accelerant's major breakthrough on Aug. 13 resulted from two overlapping catalysts. First were the company's unusually strong Q2 2026 earnings results, and second, announced at the same time, was the firm's revelation that it would be taken private by Thoma Bravo. Investors may be too late to maximize their gains on ARX stock, but the massive jump reveals important lessons about the specialty insurance industry that may pay off in other cases.

The First Major Driver: Extraordinary Earnings

Accelerant's earnings for the latest quarter were stellar, topping Wall Street expectations across multiple critical metrics. With nearly $357 million in quarterly revenue, Accelerant improved this figure by about 63% year over year (YOY). Earnings per share (EPS) of 32 cents were more than double the 14 cents reported a year earlier. Both top- and bottom-line figures were significantly higher than Wall Street's already optimistic predictions.

The magnitude of Accelerant's EPS beat, in particular, is a sign that profitability is expanding at a breakneck pace. In Q2 2025, net income attributable to common shareholders was $8.8 million; by the same quarter this year, it had climbed to nearly $79 million. Adjusted EBITDA also made major gains, indicating very healthy operating performance across multiple segments.

How Accelerant's Business Stands Out

Accelerant does not function like most insurance companies, which underwrite risk using their own balance sheets. Instead, it operates a specialty insurance exchange that connects capital providers, reinsurers, institutional investors and agents. Accelerant generates fee-based income from policies written through its exchange, allowing it to avoid taking on the insurance risk itself. This is crucial to the firm's margin growth: It can scale without taking on greater balance sheet exposure.

The company is expanding its capacity through key partnerships with third-party-capitalized insurer WoodStar Reciprocal, among others. This should help Accelerant scale its fee revenue, which may further distinguish the company from its industry peers. As Accelerant attracts increasing amounts of capital to its platform, it can facilitate more risk, generating larger volumes of fee income without increasing the company's own balance sheet risk.

The Second Major Driver: A Private Equity Deal

Thoma Bravo plans to take Accelerant private in an all-cash transaction with an enterprise value of more than $4 billion, valuing its shares at $20.25 each. This represented a significant premium over Accelerant's pre-announcement price, but after the brief spike, shares have stabilized just below that level.

While the Thoma Bravo deal may not present much of an investment opportunity now that it has been announced and investors have reacted accordingly, it does suggest that specialty insurance marketplace models may be undervalued elsewhere in the market. Thoma Bravo specializes in insurance technology platforms and is unlikely to have paid a premium approaching 50% without determining that the company was trading well below its true value.

Investors might view this as an opportunity to identify other insurance companies operating outside the traditional model and perhaps utilizing Accelerant's low-capital, fee-heavy exchange model or something similar.

This Opportunity May Have Passed, But Others Could Await

ARX shares are currently trading slightly below the $20.25 take-private price as investors factor in deal-completion risk, regulatory timelines and other concerns. While some potential arbitrage opportunities remain, it seems unlikely that Accelerant will see another one-day gain like the one it experienced in August.

Investors may want to avoid spending too much time on ARX and instead assess what about the company warranted such a premium from Thoma Bravo before seeking out those same qualities elsewhere. Two of Accelerant's competitors that may see increased investor attention following the announcement are Ryan Specialty Group Inc. (NYSE: RYAN) and Kinsale Capital Group Inc. (NYSE: KNSL). Although their share price performance has not been as strong over the last month, both companies now operate in a market that has demonstrated what a successful specialty insurance platform may be worth to investors.